|
Monalizumab Clinical Trials
4 actively recruiting trials across 4 locations
No change since May 2026
Also known as: IPH-2201, IPH2201, Immunoglobulin G4-kappa, Anti-(Homo sapiens KLRC1 (Killer Cell Lectin-like Receptor Subfamily C Member 1, NKG2-a, NKG2a, CD159A, CD94)), Humanized Monoclonal Antibody, NN-8765, NN8765 +1 more
Pipeline
Phase 2: 4
Top Sponsors
- SWOG Cancer Research Network1
- John Sfakianos1
- Hirva Mamdani1
- AstraZeneca1
Indications
- Cancer4
- Lung Cancer3
- Lung Small Cell Carcinoma, P Subtype1
- Lung Small Cell Carcinoma, N Subtype1
- Lung Small Cell Carcinoma, I Subtype1
Little Rock, Arkansas1 trial
Phase 2
Loma Linda, California1 trial
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Loma Linda University Medical Center
Phase 2
Tampa, Florida1 trial
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
Moffitt Cancer Center
Phase 2
Indianapolis, Indiana1 trial
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.